Literature DB >> 22157557

Management of neuroendocrine tumors of unknown origin.

Ariel Polish1, Maxwell T Vergo, Mark Agulnik.   

Abstract

Neuroendocrine tumors (NETs) of unknown origin account for more than 10% of all NETs. Most of these tumors are poorly differentiated and, thus, very aggressive. Establishing the location of the primary tumor can be challenging. Workup of these NETs of unknown origin includes a thorough family history, immunohistochemistry, imaging, and OctreoScan. If the location of the primary malignancy is not determined, treatment is often initiated based on the grade and level of differentiation of the tumor, with well- and moderately differentiated tumors treated as carcinoid tumors, whereas poorly differentiated tumors are treated similarly to small cell tumors. Therapy is chosen based on symptoms and with the goal of debulking tumor when feasible and safe.

Entities:  

Mesh:

Year:  2011        PMID: 22157557     DOI: 10.6004/jnccn.2011.0118

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  7 in total

1.  Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis.

Authors:  Sara De Dosso; Giorgio Treglia; Mariarosa Pascale; Adriana Tamburello; Prasanna Santhanam; Alexander S Kroiss; Ricardo Pereira Mestre; Piercarlo Saletti; Luca Giovanella
Journal:  Endocrine       Date:  2019-04-19       Impact factor: 3.633

Review 2.  Management of neuroendocrine tumors of unknown primary.

Authors:  Krystallenia Alexandraki; Anna Angelousi; Georgios Boutzios; Georgios Kyriakopoulos; Dimitra Rontogianni; Gregory Kaltsas
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

3.  Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors.

Authors:  Redmond-Craig Anderson; Erik M Velez; Bhushan Desai; Hossein Jadvar
Journal:  Nucl Med Mol Imaging       Date:  2021-01-07

Review 4.  Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.

Authors:  Michele Prisciandaro; Maria Antista; Alessandra Raimondi; Francesca Corti; Federica Morano; Giovanni Centonze; Giovanna Sabella; Alessandro Mangogna; Giovanni Randon; Filippo Pagani; Natalie Prinzi; Monica Niger; Salvatore Corallo; Erica Castiglioni di Caronno; Marco Massafra; Maria Di Bartolomeo; Filippo de Braud; Massimo Milione; Sara Pusceddu
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

Review 5.  Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review.

Authors:  Qing Pan; Wenbo Yang; Zhicai Zhang; Zengwu Shao
Journal:  Orthop Surg       Date:  2022-07-20       Impact factor: 2.279

6.  Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.

Authors:  Joshua M Francis; Adam Kiezun; Alex H Ramos; Stefano Serra; Chandra Sekhar Pedamallu; Zhi Rong Qian; Michaela S Banck; Rahul Kanwar; Amit A Kulkarni; Anna Karpathakis; Veronica Manzo; Tanupriya Contractor; Juliet Philips; Elizabeth Nickerson; Nam Pho; Susanne M Hooshmand; Lauren K Brais; Michael S Lawrence; Trevor Pugh; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Scott L Carter; Akinyemi I Ojesina; Samuel Freeman; Robert T Jones; Douglas Voet; Gordon Saksena; Daniel Auclair; Robert Onofrio; Erica Shefler; Carrie Sougnez; Jonna Grimsby; Lisa Green; Niall Lennon; Tim Meyer; Martyn Caplin; Daniel C Chung; Andreas S Beutler; Shuji Ogino; Christina Thirlwell; Ramesh Shivdasani; Sylvia L Asa; Chris R Harris; Gad Getz; Matthew Kulke; Matthew Meyerson
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

7.  Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.

Authors:  Jennifer Erdrich; Kurt B Schaberg; Michael S Khodadoust; Li Zhou; Andrew A Shelton; Brendan C Visser; James M Ford; Ash A Alizadeh; Stephen R Quake; Pamela L Kunz; John F Beausang
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.